A clinical trial of a vaccine developed by AstraZeneca and Oxford University will continue despite the death of a volunteer in Brazil, as a review did not reveal safety concerns Vincenzo PINTO AFP/FileHowever, organizers of the study said an independent review had concluded there were no safety concerns and that testing of the vaccine, developed with pharmaceutical firm AstraZeneca, would continue.
“Following careful assessment of this case in Brazil, there have been no concerns about safety of the clinical trial, and the independent review in addition to the Brazilian regulator have recommended that the trial should continue,” Oxford said in a statement. The D’Or Teaching and Research Institute , which is helping organize the tests in Brazil, said the independent review had “raised no doubts about the safety of the study, and recommended it continue.”
Half the volunteers in the final-stage clinical trial — a double-blind, randomized, controlled study — receive a placebo, IDOR said.